- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07572994
Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndrome (BIC-LIDO-MPS)
Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndrome Using Surface Electromyography (sEMG)
This study is designed to evaluate a method to improve the treatment of myofascial pain syndrome (MPS), a common condition that causes muscle pain, tenderness, and reduced movement due to the presence of trigger points in muscles.
A commonly used treatment for this condition is the injection of a local anesthetic called lidocaine into these trigger points to relieve pain. However, the pain relief from lidocaine alone may be temporary.
In this study, we are investigating whether adding a small amount of sodium bicarbonate to lidocaine can improve its effectiveness. Sodium bicarbonate may reduce the pain during injection and help the anesthetic work faster and possibly last longer.
Participants in this study will be randomly assigned into one of two groups:
One group will receive lidocaine alone. The other group will receive lidocaine mixed with sodium bicarbonate.
The injection will be performed once into the painful muscle trigger points under sterile conditions.
Pain levels will be assessed using a simple pain scale, and muscle activity will be measured using a non-invasive technique called surface electromyography (sEMG), which records muscle electrical activity. These measurements will be taken before the injection, immediately after, and during follow-up visits.
Participants may experience mild discomfort during or after the injection, but all procedures are routinely used in clinical practice. Safety measures will be in place to manage any possible side effects.
The goal of this study is to determine whether the combined injection provides better pain relief, improves muscle function, and enhances patient comfort compared to lidocaine alone.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Study Overview
This study is a randomized, parallel-group, single-blind clinical trial designed to evaluate the clinical effectiveness of adding sodium bicarbonate to lidocaine in the treatment of myofascial pain syndrome (MPS). The study compares outcomes between lidocaine alone and buffered lidocaine using surface electromyography (sEMG) and pain assessment tools.
Background
Myofascial pain syndrome is a prevalent musculoskeletal disorder characterized by the presence of myofascial trigger points, leading to localized or referred pain, functional limitation, and reduced quality of life. Although trigger point injections with lidocaine are widely used and provide rapid pain relief, their effects are often temporary and may require repeated administration.
Buffered lidocaine, achieved by adding sodium bicarbonate, has been proposed to enhance anesthetic performance by increasing the pH of the solution. This increases the proportion of the non-ionized form of lidocaine, facilitating faster onset of action, improved tissue penetration, and reduced pain during injection. However, its role in managing MPS has not been sufficiently established.
Rationale
There is currently no consensus regarding the optimal injectable solution for trigger point therapy. This study aims to determine whether buffering lidocaine with sodium bicarbonate improves clinical outcomes in terms of pain reduction, patient comfort, and muscle function compared to lidocaine alone.
Objectives
The primary objective is to evaluate the effect of adding sodium bicarbonate to lidocaine on pain reduction in patients with myofascial pain syndrome.
Secondary objectives include:
Assessing pain experienced during injection Evaluating changes in muscle activation patterns and functional recovery Study Design Type: Randomized controlled clinical trial Design: Parallel, two-arm Allocation ratio: 1:1 Blinding: Single-blind (participants blinded) Framework: Superiority Participants
Participants will be recruited from outpatient clinics of the Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Cairo University.
Eligible participants include patients diagnosed with myofascial pain syndrome presenting with active trigger points and moderate to severe pain.
Interventions
Participants will be randomly assigned into two groups:
Control Group: Injection with 2% lidocaine alone Intervention Group: Injection with 2% lidocaine buffered with sodium bicarbonate (8.4%)
The buffered solution will be freshly prepared immediately prior to injection under aseptic conditions.
All injections will be administered into identified trigger points using a standardized technique.
Outcome Measures Primary Outcome
Pain reduction assessed using:
Visual Analog Scale (VAS) Surface electromyography (sEMG) Secondary Outcome Pain during injection (VAS) Tertiary Outcome Changes in muscle activation during voluntary contraction (sEMG)
Assessments will be conducted at baseline, immediately after injection, and at follow-up visits.
Safety Considerations
All procedures will follow strict aseptic protocols. Patients will be monitored immediately after injection for any adverse reactions.
Possible risks include:
Pain at injection site Vasovagal reactions Local tissue injury Rare allergic reactions
Risk mitigation measures include proper injection technique, dose calculation, aspiration before injection, and availability of emergency equipment.
Data Collection and Analysis
Data will be collected using standardized forms and stored securely. Statistical analysis will be performed to compare outcomes between both groups, with significance set at p ≤ 0.05.
Ethical Considerations
The study will be conducted following ethical guidelines and will require approval from the institutional ethics committee. Written informed consent will be obtained from all participants prior to enrollment. Participant confidentiality will be strictly maintained.
Expected Impact
This study aims to provide evidence on whether buffering lidocaine with sodium bicarbonate improves treatment outcomes in myofascial pain syndrome. The findings may help guide clinical practice toward more effective and comfortable treatment options.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: ola mohamed Abdelfatah, bachelor
- Número de teléfono: +201122789240
- Correo electrónico: ola.abdelfatah@dentistry.cu.edu.eg
Ubicaciones de estudio
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Egipto, 22023
- Faculty of Dentistry Cairo University
-
Contacto:
- Ola mohamed Abdelfatah
- Número de teléfono: 01122789240
- Correo electrónico: ola.abdelfatah@dentistry.cu.edu.eg
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
Patients aged 16 to 70 years Clinical diagnosis of myofascial pain syndrome (MPS) Presence of active myofascial trigger points Pain duration ≥ 3 months Pain intensity ≥ 4 on the Visual Analog Scale (VAS) Trigger points located in accessible muscles No trigger point injection in the affected area within the past 3 months Ability and willingness to provide informed consent Willingness to comply with study procedures and follow-up visits
Exclusion Criteria:
Known allergy or hypersensitivity to lidocaine, sodium bicarbonate, or other amide-type local anesthetics Current use of anticoagulants or presence of bleeding disorders Local or systemic infection at or near the injection site History of fibromyalgia, cancer-related pain, or central pain syndromes Major psychiatric disorders (e.g., schizophrenia, severe depression) Recent trauma or surgery to the neck, shoulder, or back within the past 6 months Use of analgesics (e.g., NSAIDs, opioids) within 5 days prior to injection Severe systemic diseases (e.g., uncontrolled diabetes, liver failure, kidney failure, severe cardiovascular disease)
-
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Lidocaine 2% (control group)
Participants in this group will receive a single-session trigger point injection using 2% lidocaine without any additives.
The injection will be administered into the identified myofascial trigger points using a standardized technique under aseptic conditions.
|
2% lidocaine (preservative-free, without vasoconstrictor) will be administered via intramuscular injection into the identified trigger points.
Approximately 1.8 mL will be injected per point using a sterile 25-27 gauge needle.
The injection will be performed using a standardized "fast-in, fast-out" (peppering) technique.
|
|
Experimental: Lidocaine + Sodium Bicarbonate (buffered group)
Participants in this group will receive a single-session trigger point injection using 2% lidocaine combined with sodium bicarbonate.
The buffered solution is intended to reduce injection pain and enhance anesthetic effectiveness.
|
A buffered anesthetic solution will be prepared immediately before injection by mixing 2% lidocaine with 8.4% sodium bicarbonate in a ratio of 9:1 (1.8 mL lidocaine + 0.2 mL sodium bicarbonate per injection point).
The solution will be administered via intramuscular injection into trigger points using a sterile 25-27 gauge needle and standardized injection technique.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Reduction in Pain Intensity
Periodo de tiempo: Baseline, immediately after injection, and 2 weeks post-injection
|
Pain intensity will be assessed using the Visual Analog Scale (VAS) (0-10).
In addition, surface electromyography (sEMG) will be used to objectively evaluate muscle activity at rest (MVC%).
A reduction in VAS scores and sEMG activity indicates improvement.
|
Baseline, immediately after injection, and 2 weeks post-injection
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pain During Injection
Periodo de tiempo: Immediately after injection
|
Pain experienced during the injection procedure will be measured using the Visual Analog Scale (VAS) (0-10), immediately after completion of the injection.
|
Immediately after injection
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Muscle Activation Pattern
Periodo de tiempo: Baseline and 2 weeks post-injection
|
Changes in muscle activation during voluntary contraction will be assessed using surface electromyography (sEMG) (MVC%).
Improvement indicates better functional muscle recovery.
|
Baseline and 2 weeks post-injection
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Khalid elhayes, professor, cairo university oral and maxillofacial surgery department
- Director de estudio: Abdelmoez Mohamed El-Sharkawy, Associate professor, cairo University -oral and maxillofacial surgery department
- Director de estudio: Adham Yehia Zakaria, Lecturer, cairo university oral and maxillofacial surgery department
- Director de estudio: Eman hassan Elzamarany, lecturer, Department of Neurology and Clinical Physiology Faculty of Medicine, Cairo University
- Investigador principal: ola mohamed Abdelfath, cairo university oral and maxillofacial surgery department
Publicaciones y enlaces útiles
Publicaciones Generales
- Burns CA, Ferris G, Feng C, Cooper JZ, Brown MD. Decreasing the pain of local anesthesia: a prospective, double-blind comparison of buffered, premixed 1% lidocaine with epinephrine versus 1% lidocaine freshly mixed with epinephrine. J Am Acad Dermatol. 2006 Jan;54(1):128-31. doi: 10.1016/j.jaad.2005.06.043.
- McKay W, Morris R, Mushlin P. Sodium bicarbonate attenuates pain on skin infiltration with lidocaine, with or without epinephrine. Anesth Analg. 1987 Jun;66(6):572-4. No abstract available.
- Ghasemi M, Mosaffa F, Hoseini B, Behnaz F. Comparison of the Effect of Bicarbonate, Hyaluronidase, and Lidocaine Injection on Myofascial Pain Syndrome. Anesth Pain Med. 2020 Jun 23;10(3):e101037. doi: 10.5812/aapm.101037. eCollection 2020 Jun.
- Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Lauber R, Hogstrom H, Scaramozzino P, Luginbuhl M, Sieber TJ, Zbinden AM. Adding sodium bicarbonate to lidocaine enhances the depth of epidural blockade. Anesth Analg. 1998 Feb;86(2):341-7. doi: 10.1097/00000539-199802000-00024.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Dolor
- Manifestaciones neurológicas
- Enfermedades musculoesqueléticas
- Enfermedades de la Boca
- Enfermedades Estomatognáticas
- Enfermedades del Sistema Nervioso
- Enfermedades Musculares
- Enfermedades Neuromusculares
- Enfermedades reumáticas
- Enfermedades de los nervios craneales
- Enfermedades del nervio facial
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Dolor musculoesquelético
- Fibromialgia
- Síndromes de dolor miofascial
- Mialgia
- Dolor facial
- Neuralgia facial
- Químicos orgánicos
- Aniluros
- Amidas
- Compuestos anilina
- Amina
- Acetanilidas
- Químicos inorgánicos
- Compuestos de sodio
- Compuestos de carbono, inorgánicos
- Carbonatos
- Ácido carbónico
- Bicarbonatos
- Lidocaína
- Bicarbonato de sodio
Otros números de identificación del estudio
- 3-3-3
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Lidocaine 2 %
-
Kanuni Sultan Suleyman Training and Research HospitalTerminadoDolor | Migración de dispositivos intrauterinosTurquía (Türkiye)
-
Giresun UniversityTerminadoReacción adversa de lidocaína | Reacción adversa de rocuronioPavo
-
Assiut UniversityAún no reclutandoFracturas múltiples de costillas
-
University College, LondonMoorfields Eye Hospital NHS Foundation Trust; Targeted Genetics CorporationTerminadoDegeneración retinalReino Unido
-
MED-EL Elektromedizinische Geräte GesmbHTerminadoPérdida de la audición | Pérdida Auditiva Sensorineural | Pérdida Auditiva, BilateralAlemania
-
University of PecsMedical University of PecsTerminado
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)ReclutamientoHipercolesterolemia familiarEstados Unidos
-
University of PennsylvaniaNational Cancer Institute (NCI); PfizerTerminado
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)Reclutamiento
-
University of Sao Paulo General HospitalTerminadoSíndrome de vejiga hiperactivaBrasil